Compare Johnson & Johnson (JNJ) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Oxford Lane Capital Corp — how do they compare? Johnson & Johnson trades at $260.7 (market cap $626.09B), while Oxford Lane Capital Corp trades at $9.52 (market cap $909.61M). The key difference: Johnson & Johnson is far larger — about 688.3× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays the higher dividend (25.76%). Which is the better fit depends on your goals.
| JNJ | OXLC | |
|---|---|---|
Market Cap | $626.09B | $909.61M |
Volume | 6,156,228 | — |
Sector | Health | Financials |
52-Week High | $267.24 | $18.75 |
52-Week Low | $172.78 | $8.15 |
Enterprise Value | $654.37B | — |
Dividend Yield | 2.06% | 25.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
OXLC trades at $9.51, up 2.59% today, with a bullish technical signal from moving averages but a neutral RSI. The stock shows mixed fundamentals: a low P/B of 0.88 suggests undervaluation, but negative ROE and ROA highlight profitability challenges. Recent earnings misses and a sharp revenue decline in 2026 contrast with consistent $0.20 monthly dividends. News sentiment is divided, with some highlighting high yield opportunities and others warning of NAV erosion and unsustainable payouts.
The outlook is cautious due to earnings volatility and high yield sustainability concerns. Opportunities include deep discount to book value and analyst buy ratings, but risks involve persistent net income losses, negative cash flow from operations, and potential dividend cuts if NAV declines continue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
